Top

Published in:

Open Access 01-12-2024 | Review

Inflammatory markers and physical frailty: towards clinical application

Authors: Yiming Pan, Lina Ma

Published in: Immunity & Ageing | Issue 1/2024

Abstract

Global population aging poses a tremendous burden on the health care system worldwide. Frailty is associated with decreased physical reserve and is considered an important indicator of adverse events in the older population. Therefore, there is growing interest in the early diagnosis and intervention of frailty, but the cellular mechanisms responsible for frailty are still not completely understood. Chronic inflammation is related to decreased physical function and increased disease risk. Additionally, multiple human and animal studies suggest that inflammation probably plays the largest role in contributing to frailty. Some inflammatory markers have been proposed to predict physical frailty. However, there are still large gaps in knowledge related to the clinical application of these markers in frail patients. Therefore, understanding the biological processes and identifying recognized and reliable markers are urgent and pivotal tasks for geriatricians. In the present review, we broadly summarize the inflammatory markers that may have potential diagnostic and therapeutic use, thereby translating them into health care for older people with frailty in the near future.

Castro-Rodríguez M, Carnicero J, Garcia-Garcia F, et al. Frailty as a major factor in the increased risk of death and disability in older people with Diabetes. J Am Med Dir Assoc. 2016;17:949–55. https://doi.org/10.1016/j.jamda.2016.07.013CrossRefPubMed

Angulo J, El Assar M, Rodríguez-Mañas L. Frailty and Sarcopenia as the basis for the phenotypic manifestation of chronic Diseases in older adults. Mol Aspects Med. 2016;50:1–32. https://doi.org/10.1016/j.mam.2016.06.001CrossRefPubMed

Cesari M, Prince M, Thiyagarajan J, et al. Frailty: an emerging Public Health Priority. J Am Med Dir Assoc. 2016;17:188–92. https://doi.org/10.1016/j.jamda.2015.12.016CrossRefPubMed

Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, Cardiovascular Disease, and frailty. Nat Reviews Cardiol. 2018;15:505–22. https://doi.org/10.1038/s41569-018-0064-2CrossRef

Wu I, Lin C, Hsiung C. Emerging roles of frailty and inflammaging in risk assessment of age-related chronic Diseases in older adults: the intersection between aging biology and personalized medicine. BioMedicine. 2015;5:1. https://doi.org/10.7603/s40681-015-0001-1CrossRefPubMedPubMedCentral

Walker K, Walston J, Gottesman R, Kucharska-Newton A, Palta P, Windham B. Midlife systemic inflammation is Associated with Frailty in later life: the ARIC Study. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2019;74:343–9. https://doi.org/10.1093/gerona/gly045CrossRefPubMed

López-Otín C, Blasco M, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186:243–78. https://doi.org/10.1016/j.cell.2022.11.001CrossRefPubMed

Calçada D, Vianello D, Giampieri E, et al. The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: a systems biology approach. Mech Ageing Dev. 2014;138–47. https://doi.org/10.1016/j.mad.2014.01.004

Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of Disease across the life span. Nat Med. 2019;25:1822–32. https://doi.org/10.1038/s41591-019-0675-0CrossRefPubMedPubMedCentral

10.

Bellumkonda L, Tyrrell D, Hummel S, Goldstein D. Pathophysiology of Heart Failure and frailty: a common inflammatory origin? Aging Cell. 2017;16:444–50. https://doi.org/10.1111/acel.12581CrossRefPubMedPubMedCentral

11.

Martinez-Lopez N, Athonvarangkul D, Singh R. Autophagy and aging. Adv Exp Med Biol. 2015;847:73–87. https://doi.org/10.1007/978-1-4939-2404-2_3CrossRefPubMedPubMedCentral

12.

Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related Diseases. J Am Med Dir Assoc. 2013;14:877–82. https://doi.org/10.1016/j.jamda.2013.05.009CrossRefPubMed

13.

Fridovich I. Mitochondria: are they the seat of senescence? Aging Cell. 2004;3:13–6. https://doi.org/10.1046/j.1474-9728.2003.00075.xCrossRefPubMed

14.

Soysal P, Arik F, Smith L, Jackson S, Isik A. Inflammation, Frailty and Cardiovascular Disease. Adv Exp Med Biol. 2020;1216:55–64. https://doi.org/10.1007/978-3-030-33330-0_7CrossRefPubMed

15.

Zanini G, Selleri V, Lopez Domenech S, et al. Mitochondrial DNA as inflammatory DAMP: a warning of an aging immune system? Biochem Soc Trans. 2023;51:735–45. https://doi.org/10.1042/bst20221010CrossRefPubMed

16.

Conway J, Duggal A. Ageing of the gut microbiome: potential influences on immune senescence and inflammageing. Ageing Res Rev. 2021;68:101323. https://doi.org/10.1016/j.arr.2021.101323CrossRefPubMed

17.

Meyers A, Zhu X. The NLRP3 inflammasome: metabolic regulation and contribution to Inflammaging. Cells. 2020;9. https://doi.org/10.3390/cells9081808

18.

Barroso-Vilares M, Logarinho E. Chromosomal instability and pro-inflammatory response in aging. Mech Ageing Dev. 2019;182:111118doi. https://doi.org/10.1016/j.mad.2019.111118CrossRef

19.

Sendama W. The effect of ageing on the resolution of inflammation. Ageing Res Rev. 2020;57:101000. https://doi.org/10.1016/j.arr.2019.101000CrossRefPubMedPubMedCentral

20.

Salminen A. Increased immunosuppression impairs tissue homeostasis with aging and age-related Diseases. J Mol Med. 2021;99:1–20. https://doi.org/10.1007/s00109-020-01988-7CrossRefPubMed

21.

Bhusal A, Rahman M, Suk K. Hypothalamic inflammation in metabolic disorders and aging. Cell Mol Life Sci. 2021;79:32. https://doi.org/10.1007/s00018-021-04019-xCrossRefPubMed

22.

Mancuso P, Bouchard B. The impact of aging on adipose function and Adipokine Synthesis. Front Endocrinol. 2019;10:137. https://doi.org/10.3389/fendo.2019.00137CrossRef

23.

Dugué P, Hodge A, Ulvik A, et al. Association of Markers of Inflammation, the Kynurenine Pathway and B vitamins with Age and Mortality, and a signature of inflammaging. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2022;77:826–36. https://doi.org/10.1093/gerona/glab163CrossRefPubMed

24.

Barbé-Tuana F, Funchal G, Schmitz C, Maurmann R, Bauer M. The interplay between immunosenescence and age-related Diseases. Semin Immunopathol. 2020;42:545–57. https://doi.org/10.1007/s00281-020-00806-zCrossRefPubMedPubMedCentral

25.

Martemucci G, Portincasa P, Di Ciaula A, Mariano M, Centonze V, D’Alessandro A. Oxidative stress, aging, antioxidant supplementation and their impact on human health: an overview. Mech Ageing Dev. 2022;206:111707. https://doi.org/10.1016/j.mad.2022.111707CrossRefPubMed

26.

Royce G, Brown-Borg H, Deepa S. The potential role of necroptosis in inflammaging and aging. GeroScience. 2019;41:795–811. https://doi.org/10.1007/s11357-019-00131-wCrossRefPubMedPubMedCentral

27.

Cardoso A, Fernandes A, Aguilar-Pimentel J, et al. Towards frailty biomarkers: candidates from genes and pathways regulated in aging and age-related Diseases. Ageing Res Rev. 2018;47:214–77. https://doi.org/10.1016/j.arr.2018.07.004CrossRefPubMed

28.

Deretic V. Autophagy in inflammation, Infection, and immunometabolism. Immunity. 2021;54:437–53. https://doi.org/10.1016/j.immuni.2021.01.018CrossRefPubMedPubMedCentral

29.

Robb M, McInnes P, Califf R. Biomarkers and surrogate endpoints: developing common terminology and definitions. JAMA. 2016;315:1107–8. https://doi.org/10.1001/jama.2016.2240CrossRefPubMed

30.

Van Epps P, Oswald D, Higgins P, et al. Frailty has a stronger association with inflammation than age in older veterans. Immun Ageing: I a. 2016;13:27. https://doi.org/10.1186/s12979-016-0082-zCrossRefPubMedPubMedCentral

31.

Xia S, Zhang X, Zheng S, et al. An update on Inflamm-Aging: mechanisms, Prevention, and treatment. J Immunol Res. 2016;2016:8426874. https://doi.org/10.1155/2016/8426874CrossRefPubMedPubMedCentral

32.

Fried L, Tangen C, Walston J, et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2001;56:M146–156. https://doi.org/10.1093/gerona/56.3.m146CrossRefPubMed

33.

Buta B, Walston J, Godino J, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53–61. https://doi.org/10.1016/j.arr.2015.12.003CrossRefPubMed

34.

Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2007;62:722–7. https://doi.org/10.1093/gerona/62.7.722CrossRefPubMed

35.

Walston J, Bandeen-Roche K. Frailty: a tale of two concepts. BMC Med. 2015;13:185. https://doi.org/10.1186/s12916-015-0420-6CrossRefPubMedPubMedCentral

36.

Morley J, Malmstrom T, Miller D. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African americans. J Nutr Health Aging. 2012;16:601–8. https://doi.org/10.1007/s12603-012-0084-2CrossRefPubMedPubMedCentral

37.

Ma L, Tang Z, Chan P, Walston J. Novel Frailty Screening Questionnaire (FSQ) predicts 8-year Mortality in older adults in China. J Frailty Aging. 2019;8:33–8. https://doi.org/10.14283/jfa.2018.38CrossRefPubMed

38.

Fabrício-Wehbe S, Schiaveto F, Vendrusculo T, Haas V, Dantas R, Rodrigues R. Cross-cultural adaptation and validity of the ‘Edmonton Frail Scale - EFS’ in a Brazilian elderly sample. Rev Latinoam Enferm. 2009;17:1043–9. https://doi.org/10.1590/s0104-11692009000600018CrossRef

39.

Peters L, Boter H, Burgerhof J, Slaets J, Buskens E. Construct validity of the Groningen Frailty Indicator established in a large sample of home-dwelling elderly persons: evidence of stability across age and gender. Exp Gerontol. 2015;69:129–41. https://doi.org/10.1016/j.exger.2015.05.006CrossRefPubMed

40.

Gobbens R, van Assen M, Luijkx K, Wijnen-Sponselee M, Schols J. The Tilburg Frailty Indicator: psychometric properties. J Am Med Dir Assoc. 2010;11:344–55. https://doi.org/10.1016/j.jamda.2009.11.003CrossRefPubMed

41.

Pilotto A, Ferrucci L, Franceschi M, et al. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuven Res. 2008;11:151–61. https://doi.org/10.1089/rej.2007.0569CrossRef

42.

Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85 + study. Mech Ageing Dev. 2012;133:456–66. https://doi.org/10.1016/j.mad.2012.05.005CrossRefPubMed

43.

Chao C, Hsu Y, Chang P, et al. Simple self-report FRAIL scale might be more closely associated with dialysis Complications than other frailty screening instruments in rural chronic dialysis patients. Nephrol (Carlton Vic). 2015;20:321–8. https://doi.org/10.1111/nep.12401CrossRef

44.

Lu Y, Tan C, Nyunt M, et al. Inflammatory and immune markers associated with physical frailty syndrome: findings from Singapore longitudinal aging studies. Oncotarget. 2016;7:28783–95. https://doi.org/10.18632/oncotarget.8939CrossRefPubMedPubMedCentral

45.

Hsu B, Hirani V, Cumming R, et al. Cross-sectional and longitudinal relationships between inflammatory biomarkers and Frailty in Community-dwelling older men: the Concord Health and Ageing in Men Project. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2019;74:835–41. https://doi.org/10.1093/gerona/glx142CrossRefPubMed

46.

Singer J, Diamond J, Gries C, et al. Frailty Phenotypes, disability, and outcomes in adult candidates for lung transplantation. Am J Respir Crit Care Med. 2015;192:1325–34. https://doi.org/10.1164/rccm.201506-1150OCCrossRefPubMedPubMedCentral

47.

Welstead M, Muniz-Terrera G, Russ T, et al. Inflammation as a risk factor for the development of frailty in the Lothian Birth Cohort 1936. Exp Gerontol. 2020;139:111055. https://doi.org/10.1016/j.exger.2020.111055CrossRefPubMedPubMedCentral

48.

Pedersen L, Hojman P. Muscle-to-organ cross talk mediated by myokines. Adipocyte. 2012;1:164–7. https://doi.org/10.4161/adip.20344CrossRefPubMedPubMedCentral

49.

Addison O, LaStayo P, Dibble L, Marcus R. Inflammation, aging, and adiposity: implications for physical therapists. J Geriatric Phys Therapy (2001). 2012;35:86–94. https://doi.org/10.1519/JPT.0b013e3182312b14CrossRef

50.

De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579:2035–9. https://doi.org/10.1016/j.febslet.2005.02.055CrossRefPubMed

51.

McKechnie D, Patel M, Papacosta A, et al. Associations between inflammation, coagulation, cardiac strain and injury, and subclinical vascular Disease with frailty in older men: a cross-sectional study. BMC Geriatr. 2022;22:405. https://doi.org/10.1186/s12877-022-03106-3CrossRefPubMedPubMedCentral

52.

Tembo M, Holloway-Kew K, Bortolasci C, et al. Association between serum interleukin-6 and frailty in older men: cross-sectional data. Eur Geriatr Med. 2021;12:887–92. https://doi.org/10.1007/s41999-021-00490-8CrossRefPubMed

53.

Samson L, Buisman A, Ferreira J, et al. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. Clin Translational Immunol. 2022;11:e1374. https://doi.org/10.1002/cti2.1374CrossRef

54.

Buigues C, Navarro-Martínez R, Sánchez-Martínez V, Serrano-Carrascosa M, Rubio-Briones J, Cauli O. Interleukin-6 and Lymphocyte Count Associated and predicted the progression of Frailty syndrome in Prostate Cancer patients undergoing antiandrogen therapy. Cancers. 2020;12. https://doi.org/10.3390/cancers12071716

55.

Langmann G, Perera S, Ferchak M, Nace D, Resnick N, Greenspan S. Inflammatory markers and Frailty in Long-Term Care residents. J Am Geriatr Soc. 2017;65:1777–83. https://doi.org/10.1111/jgs.14876CrossRefPubMedPubMedCentral

56.

Gómez-Rubio P, Trapero I, Cauli O, Buigues C. Salivary IL-6 concentration is Associated with Frailty Syndrome in older individuals. Diagnostics (Basel Switzerland). 2022;12. https://doi.org/10.3390/diagnostics12010117

57.

Walston J, Fallin M, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet. 2007;122:485–94. https://doi.org/10.1007/s00439-007-0428-xCrossRefPubMed

58.

Pansarasa O, Mimmi M, Davin A, Giannini M, Guaita A, Cereda C. Inflammation and cell-to-cell communication, two related aspects in frailty. Immun Ageing: I a. 2022;19:49. https://doi.org/10.1186/s12979-022-00306-8CrossRefPubMedPubMedCentral

59.

Kamper R, Alcazar J, Andersen L, et al. Associations between inflammatory markers, body composition, and physical function: the Copenhagen Sarcopenia Study. J cachexia Sarcopenia Muscle. 2021;12:1641–52. https://doi.org/10.1002/jcsm.12832CrossRefPubMedPubMedCentral

60.

Son D, Song S, Lee Y, Association Between C-R, Protein. Relative handgrip strength in postmenopausal Korean women aged 45–80 years: a cross-sectional study. Clin Interv Aging. 2022;17:971–8. https://doi.org/10.2147/cia.S356947CrossRefPubMedPubMedCentral

61.

Schaap L, Pluijm S, Deeg D, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2009;64:1183–9. https://doi.org/10.1093/gerona/glp097CrossRefPubMed

62.

Tay L, Lim W, Chan M, Ye R, Chong M. The Independent role of inflammation in physical Frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s Disease. J Nutr Health Aging. 2016;20:288–99. https://doi.org/10.1007/s12603-015-0617-6CrossRefPubMed

63.

Mekli K, Nazroo J, Marshall A, Kumari M, Pendleton N. Proinflammatory genotype is associated with the frailty phenotype in the English Longitudinal Study of Ageing. Aging Clin Exp Res. 2016;28:413–21. https://doi.org/10.1007/s40520-015-0419-zCrossRefPubMed

64.

Leng S, Tian X, Matteini A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults. Age Ageing. 2011;40:475–81. https://doi.org/10.1093/ageing/afr047CrossRefPubMedPubMedCentral

65.

Lang C, Frost R. Sepsis-induced suppression of skeletal muscle translation initiation mediated by Tumor necrosis factor alpha. Metab Clin Exp. 2007;56:49–57. https://doi.org/10.1016/j.metabol.2006.08.025CrossRefPubMed

66.

Aguirre L, Jan I, Fowler K, Waters D, Villareal D, Armamento-Villareal R. Testosterone and adipokines are determinants of physical performance, strength, and Aerobic Fitness in Frail, obese, older adults. Int J Endocrinol. 2014;2014. https://doi.org/10.1155/2014/507395

67.

Castro-Herrera V, Lown M, Fisk H, et al. Relationships between Age, Frailty, length of Care Home Residence and biomarkers of immunity and inflammation in Older Care Home residents in the United Kingdom. Front Aging. 2021;2:599084. https://doi.org/10.3389/fragi.2021.599084CrossRefPubMedPubMedCentral

68.

Gonçalves R, Maciel Á, Rolland Y, Vellas B, de Souto Barreto P. Frailty biomarkers under the perspective of geroscience: a narrative review. Ageing Res Rev. 2022;81:101737. https://doi.org/10.1016/j.arr.2022.101737CrossRefPubMed

69.

Zhang L, Zeng X, He F, Huang X. Inflammatory biomarkers of frailty: a review. Exp Gerontol. 2023;179:112253. https://doi.org/10.1016/j.exger.2023.112253CrossRefPubMed

70.

Xu Y, Wang M, Chen D, Jiang X, Xiong Z. Inflammatory biomarkers in older adults with frailty: a systematic review and meta-analysis of cross-sectional studies. Aging Clin Exp Res. 2022;34:971–87. https://doi.org/10.1007/s40520-021-02022-7CrossRefPubMed

71.

Correia-Melo C, Birch J, Fielder E, et al. Rapamycin improves healthspan but not inflammaging in nfκb1 mice. Aging Cell. 2019;18:e12882. https://doi.org/10.1111/acel.12882CrossRefPubMed

72.

Pérez-Martínez L, Romero L, Muñoz-Galván S, et al. Implications of maraviroc and/or rapamycin in a mouse model of fragility. Aging. 2020;12:8565–82. https://doi.org/10.18632/aging.103167CrossRefPubMedPubMedCentral

73.

Ma L, Nidadavolu L, Yang H, et al. Targeted deletion of Interleukin-6 in a mouse model of chronic inflammation demonstrates opposing roles in aging: benefit and harm. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2021;76:211–5. https://doi.org/10.1093/gerona/glaa156CrossRefPubMed

74.

Varadhan R, Yao W, Matteini A, et al. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2014;69:165–73. https://doi.org/10.1093/gerona/glt023CrossRefPubMed

75.

McAdams-DeMarco M, Ying H, Thomas A, et al. Frailty, inflammatory markers, and Waitlist Mortality among patients with end-stage Renal Disease in a prospective cohort study. Transplantation. 2018;102:1740–6. https://doi.org/10.1097/tp.0000000000002213CrossRefPubMedPubMedCentral

76.

Piggott D, Varadhan R, Mehta S, et al. Frailty, inflammation, and Mortality among persons Aging with HIV Infection and Injection Drug Use. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2015;70:1542–7. https://doi.org/10.1093/gerona/glv107CrossRefPubMedPubMedCentral

77.

Calvani R, Picca A, Marini F, et al. Identification of biomarkers for physical frailty and sarcopenia through a new multi-marker approach: results from the BIOSPHERE study. GeroScience. 2021;43:727–40. https://doi.org/10.1007/s11357-020-00197-xCrossRefPubMed

78.

Marzetti E, Picca A, Marini F, et al. Inflammatory signatures in older persons with physical frailty and sarcopenia: the frailty cytokinome at its core. Exp Gerontol. 2019;122:129–38. https://doi.org/10.1016/j.exger.2019.04.019CrossRefPubMed

79.

Picca A, Coelho-Junior H, Calvani R, Marzetti E, Vetrano D. Biomarkers shared by frailty and sarcopenia in older adults: a systematic review and meta-analysis. Ageing Res Rev. 2022;73:101530. https://doi.org/10.1016/j.arr.2021.101530CrossRefPubMed

80.

Dupont J, Vercauteren L, Amini N, et al. Are inflammatory markers associated with sarcopenia-related traits in older adults with Sarcopenia? - a cross-sectional analysis of the ENHANce study. Exp Gerontol. 2023;178:112196. https://doi.org/10.1016/j.exger.2023.112196CrossRefPubMed

81.

Byrne T, Cooke J, Bambrick P, McNeela E, Harrison M. Circulating inflammatory biomarker responses in intervention trials in frail and sarcopenic older adults: a systematic review and meta-analysis. Exp Gerontol. 2023;177:112199. https://doi.org/10.1016/j.exger.2023.112199CrossRefPubMed

82.

Trombetti A, Hars M, Pahor M, McDermott M, Fielding R. Effect of physical activity on Frailty. Ann Intern Med. 2018;169:267. https://doi.org/10.7326/l18-0243CrossRefPubMed

83.

Kovalchuk A, Wang B, Li D, et al. sativaFighting the Storm: could novel anti-TNFα and anti-IL-6 cultivars tame cytokine Storm in COVID-19? Aging. 2021;13:1571–90. https://doi.org/10.18632/aging.202500CrossRefPubMedPubMedCentral

84.

Angulo J, El Assar M, Álvarez-Bustos A, Rodríguez-Mañas L. Physical activity and exercise: strategies to manage frailty. Redox Biol. 2020;35:101513doi. https://doi.org/10.1016/j.redox.2020.101513CrossRef

Title: Inflammatory markers and physical frailty: towards clinical application
Authors: Yiming Pan
Lina Ma
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Immunity & Ageing / Issue 1/2024
Electronic ISSN: 1742-4933
DOI: https://doi.org/10.1186/s12979-023-00410-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Sexual dimorphism in atherosclerotic plaques of aged Ldlr−/− mice

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence

Irisin inhibits microglial senescence via TFAM-mediated mitochondrial metabolism in a mouse model of tauopathy

Neuroimmunology and ageing – the state of the art

Growth and longevity modulation through larval environment mediate immunosenescence and immune strategy of Tenebrio molitor

The interplay between obesity, immunosenescence, and insulin resistance

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials